Novo Nordisk Eli Lilly Lawsuit: What the Case Turns On
Witfire Elite · Litigation Risk Brief · GLP-1 Series No. 04 Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win…
Read the analysis → 01 / Intelligence
Latest Pharma Intelligence
Decision-useful coverage for executives, investors, regulators and scientists.
Eplontersen CARDIO-TTRansform Miss: ATTR-CM Analysis
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Achieve Cytisinicline CRL: Rejection That Did Not Break the Company
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-07 Achieve’s Cytisinicline CRL: The Rejection That Was Priced Before It Arrived Same…
Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…
AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s
Witfire Elite · Licensing Risk Brief · CNS AlzeCure’s $2.2 Billion NeuroRestore Deal Is a Risk Transfer, Not a Victory AlzeCure did not prove…
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Witfire Elite · Launch Execution · Competitive Strategy Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion…
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-05 FDA Issues CRL to Sobi for NASP: The Agency Rejected the Control…
02 / Breaking Analysis
Consequences, not headlines
Original analysis connecting scientific evidence, regulatory decisions and market value.
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Witfire Elite · Competitive Strategy · Japan Pharma Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study.…
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case Studies Witfire Elite View Revolution Medicines Built a $4.3 Billion Wall Around…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Moderna Flu Vaccine Reversal FDA Refused to…
03 / Coverage
The pharma decision map
Regulatory Radar
FDA & Regulatory Intelligence
Capital & Deals
Investments
Market Signals
Stock Market
- Eli Lilly Retatrutide Phase 3 Results at ADA 2026
- The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy
- Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
- Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
Witfire Elite Pharma News
July 2026 · Vol. I, No. 2
Chokepoints & Catalysts
The monthly issueWitfire Elite Magazine
Where science meets strategy and breaks.
Witfire Elite Review, July 2026 -The Weakest Layer: The Stabilizer Ceiling, Eplontersen's CARDIO-TTRansform Miss, Unicycive OLC CRL.
Read the digital issue →